The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients
- 29 March 2012
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 91 (8) , 1257-1264
Abstract
Studies on pharmacokinetics and pharmacodynamics of high-dose methotrexate chemotherapy (HD-MTX) in elderly primary central nervous system lymphoma (PCNSL) patients are rare. MTX exposure time has recently been proposed as an outcome determining factor in PCNSL. We investigated 49 immunocompetent PCNSL patients (female N = 30, male N = 19, median age 73 years) who were treated according to HD-MTX-based protocols. A two-compartment pharmacokinetic model was used to describe the MTX clearance. Response to treatment was assessed by MRI. We used multivariable models to investigate the association between MTX exposure and tumor response as well as survival. Dose normalized MTX peak serum levels [C max, μmol/L g] and dose normalized area under the curve [AUCdn, μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P < 0.001; 373.2 (f) vs. 271.9 (m), P = 0.008]. Increasing AUC was inversely correlated with tumor response. AUC values above 2,126 h μmol/L were independently associated with shorter overall and progression-free survival [hazard ratio (HR), 4.56, 95 % CI 1.74–11.94; HR 2.87, 95 % CI 1.18–7.00]. Exceedingly high MTX AUC levels can have a negative impact on progression-free and overall survivals in elderly PCNSL patients.Keywords
This publication has 26 references indexed in Scilit:
- Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexateBritish Journal of Clinical Pharmacology, 2011
- Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapyLeukemia & Lymphoma, 2011
- Methods to evaluate renal function in elderly patients: a systematic literature reviewAge and Ageing, 2010
- Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphomaBritish Journal of Clinical Pharmacology, 2010
- Characteristics and outcomes of elderly patients with primary central nervous system lymphomaCancer, 2010
- Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trialBritish Journal of Cancer, 2010
- High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancyBiopharmaceutics & Drug Disposition, 2009
- Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapyBritish Journal of Clinical Pharmacology, 2008
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target TissuesJournal of Clinical Investigation, 1973